Видео ютуба по тегу Olaparib

#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi
#ESMO21 Highlights on maintenance olaparib in ovarian cancer previously treated with PARPi
Dr. Robson on the Toxicity Profile of Olaparib in Breast Cancer
Dr. Robson on the Toxicity Profile of Olaparib in Breast Cancer
The story of olaparib: a life-saving cancer drug
The story of olaparib: a life-saving cancer drug
7-year OS from SOLO1: sustained benefit with maintenance olaparib
7-year OS from SOLO1: sustained benefit with maintenance olaparib
Anne talks about ovarian cancer and drug olaparib
Anne talks about ovarian cancer and drug olaparib
OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer | Judy Garber
OlympiA: Adjuvant olaparib delays recurrence of BRCA-mutant breast cancer | Judy Garber
Case 2: Olaparib in BRCA-Mutated Ovarian Cancer
Case 2: Olaparib in BRCA-Mutated Ovarian Cancer
OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer
OlympiA: adjuvant olaparib in gBRCAm, HER2-negative, high-risk, early breast cancer
POLAR: pembrolizumab and olaparib in HRD-positive pancreatic cancer
POLAR: pembrolizumab and olaparib in HRD-positive pancreatic cancer
Predictors of Response to Olaparib: Looking Beyond BRCA
Predictors of Response to Olaparib: Looking Beyond BRCA
SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib
SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib
Olaparib Maintenance for Recurrent Ovarian Cancer
Olaparib Maintenance for Recurrent Ovarian Cancer
Exploring the use of olaparib in advanced breast cancer
Exploring the use of olaparib in advanced breast cancer
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
The PAOLA-1 study: olaparib and bevacizumab for ovarian cancer
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
Selecting patients to be treated with maintenance olaparib in the PAOLA-1 trial
Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer
Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management
PARP Inhibitor Olaparib Exceeds Expectations in BRCA+ Pancreatic Cancer Management
SOLO3 Highlights Toxicities With Olaparib in Ovarian Cancer
SOLO3 Highlights Toxicities With Olaparib in Ovarian Cancer
Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC
Dr. Agarwal on the Safety Profile of Olaparib in HRR Gene-Mutant mCRPC